A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 420 participants.
Also called NCT02119819
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 420 participants
- Sponsor
- Registry
-
NCT02119819 -
2013-003552-21
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Greece, Mexico, Poland, Puerto Rico, Romania
- Registry status
- Completed
Technical summary
Registry record NCT02119819. Randomized; double masking; primary purpose treatment. Start 2014-04 (registry gives no type); primary completion 2015-08 (actual). Results posted on 2021-04-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- LY2944876
- Intervention (Drug)
- Exenatide extended-release
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Metformin
- Lead sponsor
- OPKO Health, Inc.
Record details
- Record id
cardio:ct-nct02119819- Content hash
da161ea13d4452c0e87c3ad193c1f6e4c0fd25d4db053cba380b778b22fc2a3d